Study to Investigate the Efficacy and Safety of GL2702 GLARS-NF1tablet and Harnal-D - Tablet in BPH Patients With LUTS

NCT02303769 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

309

Enrollment

INDUSTRY

Sponsor class

Conditions

Benign Prostatic Hyperplasia

Interventions

DRUG: Tamsulosin HCL 0.4mg
DRUG: Tamsulosin HCL 0.2mg

Sponsor

GL Pharm Tech Corporation